E2F3 and ovarian carcinoma: Importantly, this study with NXP800, a clinical-stage developmental HSF1 pathway inhibitor currently being trialed in ovarian cancer, supports its clinical evaluation as a novel therapeutic strategy for patients suffering from mCRPC, whose tumors have evidence of spliced AR, increased E2F1 to E2F3, and MYC function (42).